| Date Filed | Type | Description |
| 05/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/01/2023 |
4
| Henn Matthew R. (See Remarks) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 35,000 options to buy
@ $10.84, valued at
$379.4k
|
|
| 02/07/2023 |
4
| Ege David S. (See Remarks) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 47,500 restricted stock units
@ $0
Granted 95,000 options to buy
@ $5.5, valued at
$522.5k
|
|
| 02/07/2023 |
4
| von Moltke Lisa (See Remarks) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 47,500 restricted stock units
@ $0
Granted 95,000 options to buy
@ $5.5, valued at
$522.5k
|
|
| 02/07/2023 |
4
| Henn Matthew R. (See Remarks) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 45,000 restricted stock units
@ $0
Granted 90,000 options to buy
@ $5.5, valued at
$495k
|
|
| 02/07/2023 |
4
| DesRosier Thomas (Chief Legal Officer and EVP) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 42,500 restricted stock units
@ $0
Granted 85,000 options to buy
@ $5.5, valued at
$467.5k
|
|
| 02/07/2023 |
4
| Shaff Eric D. (CEO and President) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 125,000 restricted stock units
@ $0
Granted 250,000 options to buy
@ $5.5, valued at
$1.4M
|
|
| 02/07/2023 |
4
| Arkowitz David (CFO) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 42,500 restricted stock units
@ $0
Granted 85,000 options to buy
@ $5.5, valued at
$467.5k
|
|
| 02/07/2023 |
4
| Young Teresa L. (See Remarks) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 42,500 restricted stock units
@ $0
Granted 85,000 restricted stock units
@ $0
Granted 85,000 options to buy
@ $5.5, valued at
$467.5k
|
|
| 02/07/2023 |
4
| Cloghessy Paula (See Remarks) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 47,500 restricted stock units
@ $0
Granted 95,000 options to buy
@ $5.5, valued at
$522.5k
|
|
| 01/05/2023 |
4
| Fraser Claire (Director) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 48,000 options to buy
@ $5.47, valued at
$262.6k
|
|
| 01/05/2023 |
3
| Fraser Claire (Director) has filed a Form 3 on Seres Therapeutics, Inc. |
| 10/31/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/31/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/09/2022 |
4
| Henn Matthew R. (See Remarks) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 35,000 options to buy
@ $10.84, valued at
$379.4k
|
|
| 07/07/2022 |
3
| Flagship Pioneering Fund VII General Partner LLC (10% Owner) has filed a Form 3 on Seres Therapeutics, Inc. |
| 07/07/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/06/2022 |
4
| Henn Matthew R. (See Remarks) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 47,619 shares
@ $3.15, valued at
$150k
|
|
| 07/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/06/2022 |
4
| Kender Richard N (Director) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 63,492 shares
@ $3.15, valued at
$200k
|
|
| 07/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/06/2022 |
4
| Dere Willard H (Director) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 31,746 shares
@ $3.15, valued at
$100k
|
|
| 07/06/2022 |
4
| Shaff Eric D. (CEO and President) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 63,492 shares
@ $3.15, valued at
$200k
|
|
| 07/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/06/2022 |
4
| Biondi Paul (Director) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 47,619 shares
@ $3.15, valued at
$150k
|
|
| 06/24/2022 |
4
| Kender Richard N (Director) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 35,000 options to buy
@ $3.22, valued at
$112.7k
|
|
| 06/24/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/24/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/24/2022 |
4
| Biondi Paul (Director) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 35,000 options to buy
@ $3.22, valued at
$112.7k
|
|
| 06/24/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/24/2022 |
4
| Kender Richard N (Director) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 35,000 options to buy
@ $3.22, valued at
$112.7k
|
|
|